[2] Patients should contact their GP if they experience: Side effects from B12 injections (though these are rare and usually mild) Difficulty attending scheduled injection appointments, as missed doses may lead to symptom recurrence New symptoms developing during treatment Concerns about treatment effectiveness or duration Changes in other medications that might affect B12 absorption Suspected adverse reactions to B12 treatment can be reported through the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk)
in general, hospitals cannot pick and choose which measures of the Overall Hospital Quality Star Rating they submit, and cannot choose to have ( any measure withheld from public reporting
It is not intended for human or veterinary use, clinical administration, diagnostic procedures, or any form of therapeutic use
The goal is to help readers identify useful questions, not to convert product language into unsupported medical claims
Because BPC-157 is actively listed in Category 2, the FDA has determined that it poses significant safety risks, specifically regarding immunogenicity, structural impurities, and a distinct lack of human safety data
